| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453750 | Lung Cancer | 2018 | 7 Pages |
Abstract
Osimertinib had higher response rate, longer PFS and milder side effects than docetaxel-bevacizumab in third-line therapy in patients with EGFR T790â¯M positive advanced NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Keke Nie, Zhongfa Zhang, Chunling Zhang, Chuanxin Geng, Ling Zhang, Xiajuan Xu, Shichao Liu, Songping Wang, Xingjun Zhuang, Ketao Lan, Youxin Ji,